Latest News

Chicago, Illinois – Liver disease specialists at the University of Chicago Medicine will soon begin prescribing a first-of-its-kind drug for treating advanced metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly known as nonalcoholic fatty liver disease (NAFLD). Resmetirom (to be sold under the brand name Rezdiffra), received FDA approval on March 14, 2024....
San Diego, Ca – University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Hematology (ASH) Annual Meeting, held Dec. 9-12 in San Diego, California. Trial finds new drug shows promise to treat Chronic Lymphocytic Leukemia (CLL) Phase 2 clinical trial results suggest a new drug...